Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | La Merie | Competitor Analysis: Immunotoxins

Competitor Analysis: Immunotoxins

The present Competitive Intelligence Report about Immunotoxins provides a competitor evaluation in the field of tumor targeted toxins by means of antibodies or proteins for treatment of cancer as of July 2009.

Immunotoxin therapy is a promising molecular cancer treatment strategy. Its main advantage is seletive cytotoxicity towards tumor cells and minimal toxicity in normal tissues.The clinical development of immunotoxins in the treatment of solid tumors has been impeded in part, by the induction of an immune response directed primarily against the toxin moiety, and in part by loss of activity of the fusion protein, e.g. by sterical hindrance in the case of large toxin moieties. Strategies to overcome these limitations and improve the clinical performance of immunotoxins may be to reduce immunogenicity by removing the T-cell epitopes and use bivalent or bispecific constructs as next generation molecules. A further possibility is to enhance the catalytic activity of the toxin while at the same time mitigating the unwanted systemic toxicity. At present ten immunotoxins are in phase II or higher stages of clinical development and eight projects in early clinical evaluation.

The report includes a compilation of current active projects in research and development of immunotoxins in oncology. In addition, the report lists company-specific R&D pipelines of immunotoxins. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

Index

Immunotoxins

Corporate Immunocytokine R&D Pipelines

About La Merie

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages: 26

Release Date: July of 2009

Format: PDF

Product Code: LMCA0045

License

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions